Involvement of hepcidin in the anemia of multiple myeloma

Sanjai Sharma, Elizabeta Nemeth, Yi Hsiang Chen, Julia Goodnough, Alissa Huston, G. David Roodman, Tomas Ganz, Alan Lichtenstein

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Purpose: Hepcidin is a liver-produced peptide implicated in the anemia of inflammation. Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma. Experimental Design: Urinary hepcidin and serum levels of IL-6, ferritin, C-reactive protein, tumor necrosis factor-α, and IL-1 ß were studied in newly diagnosed myeloma patients. In vitro hepcidin induction assay was assessed by real-time PCR assay. Results: Pretreatment urinary hepcidin levels in 44 patients with stage III multiple myeloma were 3-fold greater than normal controls. In the subset of multiple myeloma patients without renal insufficiency (n = 27), a marked inverse correlation was seen between hemoglobin at diagnosis and urinary hepcidin level (P = 0.014) strongly supporting a causal relationship between up-regulated hepcidin expression and anemia. The urinary hepcidin also significantly (P > 0.05) correlated with serum ferritin and C-reactive protein, whereas its correlation with serum IL-6 levels was of borderline significance (P - 0.06). Sera from 14 multiple myeloma patients, with known elevated urinary hepcidin, significantly induced hepcidin mRNA in the Hep3B cells, whereas normal sera had no effect. For 10 patients, the ability of anti-IL-6 and anti-IL-6 receptor antibodies to prevent the serum-induced hepcidin RNA was tested. In 6 of these patients, hepcidin induction was abrogated by the anti-IL-6 antibodies, but in the other 4 patients, the neutralizing antibodies had no effect. Conclusions: These results indicate hepcidin is up-regulated in multiple myeloma patients by both IL-6-dependent and IL-6-independent mechanisms and may play a role in the anemia of multiple myeloma

Original languageEnglish (US)
Pages (from-to)3262-3267
Number of pages6
JournalClinical Cancer Research
Volume14
Issue number11
DOIs
StatePublished - Jun 1 2008
Externally publishedYes

Fingerprint

Hepcidins
Multiple Myeloma
Anemia
Interleukin-6
Serum
Ferritins
C-Reactive Protein
Interleukin-6 Receptors
Antibodies
Neutralizing Antibodies
Interleukin-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sharma, S., Nemeth, E., Chen, Y. H., Goodnough, J., Huston, A., Roodman, G. D., ... Lichtenstein, A. (2008). Involvement of hepcidin in the anemia of multiple myeloma. Clinical Cancer Research, 14(11), 3262-3267. https://doi.org/10.1158/1078-0432.CCR-07-4153

Involvement of hepcidin in the anemia of multiple myeloma. / Sharma, Sanjai; Nemeth, Elizabeta; Chen, Yi Hsiang; Goodnough, Julia; Huston, Alissa; Roodman, G. David; Ganz, Tomas; Lichtenstein, Alan.

In: Clinical Cancer Research, Vol. 14, No. 11, 01.06.2008, p. 3262-3267.

Research output: Contribution to journalArticle

Sharma, S, Nemeth, E, Chen, YH, Goodnough, J, Huston, A, Roodman, GD, Ganz, T & Lichtenstein, A 2008, 'Involvement of hepcidin in the anemia of multiple myeloma', Clinical Cancer Research, vol. 14, no. 11, pp. 3262-3267. https://doi.org/10.1158/1078-0432.CCR-07-4153
Sharma, Sanjai ; Nemeth, Elizabeta ; Chen, Yi Hsiang ; Goodnough, Julia ; Huston, Alissa ; Roodman, G. David ; Ganz, Tomas ; Lichtenstein, Alan. / Involvement of hepcidin in the anemia of multiple myeloma. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 11. pp. 3262-3267.
@article{f32972d8c0c24d788d6bff109534002f,
title = "Involvement of hepcidin in the anemia of multiple myeloma",
abstract = "Purpose: Hepcidin is a liver-produced peptide implicated in the anemia of inflammation. Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma. Experimental Design: Urinary hepcidin and serum levels of IL-6, ferritin, C-reactive protein, tumor necrosis factor-α, and IL-1 {\ss} were studied in newly diagnosed myeloma patients. In vitro hepcidin induction assay was assessed by real-time PCR assay. Results: Pretreatment urinary hepcidin levels in 44 patients with stage III multiple myeloma were 3-fold greater than normal controls. In the subset of multiple myeloma patients without renal insufficiency (n = 27), a marked inverse correlation was seen between hemoglobin at diagnosis and urinary hepcidin level (P = 0.014) strongly supporting a causal relationship between up-regulated hepcidin expression and anemia. The urinary hepcidin also significantly (P > 0.05) correlated with serum ferritin and C-reactive protein, whereas its correlation with serum IL-6 levels was of borderline significance (P - 0.06). Sera from 14 multiple myeloma patients, with known elevated urinary hepcidin, significantly induced hepcidin mRNA in the Hep3B cells, whereas normal sera had no effect. For 10 patients, the ability of anti-IL-6 and anti-IL-6 receptor antibodies to prevent the serum-induced hepcidin RNA was tested. In 6 of these patients, hepcidin induction was abrogated by the anti-IL-6 antibodies, but in the other 4 patients, the neutralizing antibodies had no effect. Conclusions: These results indicate hepcidin is up-regulated in multiple myeloma patients by both IL-6-dependent and IL-6-independent mechanisms and may play a role in the anemia of multiple myeloma",
author = "Sanjai Sharma and Elizabeta Nemeth and Chen, {Yi Hsiang} and Julia Goodnough and Alissa Huston and Roodman, {G. David} and Tomas Ganz and Alan Lichtenstein",
year = "2008",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-07-4153",
language = "English (US)",
volume = "14",
pages = "3262--3267",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Involvement of hepcidin in the anemia of multiple myeloma

AU - Sharma, Sanjai

AU - Nemeth, Elizabeta

AU - Chen, Yi Hsiang

AU - Goodnough, Julia

AU - Huston, Alissa

AU - Roodman, G. David

AU - Ganz, Tomas

AU - Lichtenstein, Alan

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Purpose: Hepcidin is a liver-produced peptide implicated in the anemia of inflammation. Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma. Experimental Design: Urinary hepcidin and serum levels of IL-6, ferritin, C-reactive protein, tumor necrosis factor-α, and IL-1 ß were studied in newly diagnosed myeloma patients. In vitro hepcidin induction assay was assessed by real-time PCR assay. Results: Pretreatment urinary hepcidin levels in 44 patients with stage III multiple myeloma were 3-fold greater than normal controls. In the subset of multiple myeloma patients without renal insufficiency (n = 27), a marked inverse correlation was seen between hemoglobin at diagnosis and urinary hepcidin level (P = 0.014) strongly supporting a causal relationship between up-regulated hepcidin expression and anemia. The urinary hepcidin also significantly (P > 0.05) correlated with serum ferritin and C-reactive protein, whereas its correlation with serum IL-6 levels was of borderline significance (P - 0.06). Sera from 14 multiple myeloma patients, with known elevated urinary hepcidin, significantly induced hepcidin mRNA in the Hep3B cells, whereas normal sera had no effect. For 10 patients, the ability of anti-IL-6 and anti-IL-6 receptor antibodies to prevent the serum-induced hepcidin RNA was tested. In 6 of these patients, hepcidin induction was abrogated by the anti-IL-6 antibodies, but in the other 4 patients, the neutralizing antibodies had no effect. Conclusions: These results indicate hepcidin is up-regulated in multiple myeloma patients by both IL-6-dependent and IL-6-independent mechanisms and may play a role in the anemia of multiple myeloma

AB - Purpose: Hepcidin is a liver-produced peptide implicated in the anemia of inflammation. Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma. Experimental Design: Urinary hepcidin and serum levels of IL-6, ferritin, C-reactive protein, tumor necrosis factor-α, and IL-1 ß were studied in newly diagnosed myeloma patients. In vitro hepcidin induction assay was assessed by real-time PCR assay. Results: Pretreatment urinary hepcidin levels in 44 patients with stage III multiple myeloma were 3-fold greater than normal controls. In the subset of multiple myeloma patients without renal insufficiency (n = 27), a marked inverse correlation was seen between hemoglobin at diagnosis and urinary hepcidin level (P = 0.014) strongly supporting a causal relationship between up-regulated hepcidin expression and anemia. The urinary hepcidin also significantly (P > 0.05) correlated with serum ferritin and C-reactive protein, whereas its correlation with serum IL-6 levels was of borderline significance (P - 0.06). Sera from 14 multiple myeloma patients, with known elevated urinary hepcidin, significantly induced hepcidin mRNA in the Hep3B cells, whereas normal sera had no effect. For 10 patients, the ability of anti-IL-6 and anti-IL-6 receptor antibodies to prevent the serum-induced hepcidin RNA was tested. In 6 of these patients, hepcidin induction was abrogated by the anti-IL-6 antibodies, but in the other 4 patients, the neutralizing antibodies had no effect. Conclusions: These results indicate hepcidin is up-regulated in multiple myeloma patients by both IL-6-dependent and IL-6-independent mechanisms and may play a role in the anemia of multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=50349085287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349085287&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4153

DO - 10.1158/1078-0432.CCR-07-4153

M3 - Article

C2 - 18519751

AN - SCOPUS:50349085287

VL - 14

SP - 3262

EP - 3267

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -